Literature DB >> 434672

Dementia, renal failure, and brain aluminum.

A I Arieff, J D Cooper, D Armstrong, V C Lazarowitz.   

Abstract

Dialysis dementia is a progressive and usually fatal neurologic syndrome occurring in patients on chronic hemodialysis. These patients may also have elevated levels of aluminum (Al+3) in the cerebral cortex. Possible relations between brain Al+3, increased Al+3 intake, and dementia were evaluated. Studies were done in seven groups of patients and five groups of experimental animals. In both normal dogs and rats and those with renal failure, oral Al+3 loading (Al[OH]3), resulted in significant increases of brain Al+3 (P less than 0.01). In patients with renal failure, who were neither demented nor treated with dialysis, brain Al+3 was more than seven times normal (P less than 0.01), whereas in patients with dialysis dementia, mean brain Al+3 was more than 15 times normal. However, the two groups were not significantly different. Brain Al+3 was also significantly elevated in patients who had either metastatic cancer or hepatic coma. Apparently brain Al+3 can be elevated as a consequence of Al+3 loading, renal failure, and abnormalities of the blood-brain barrier. It is most likely that dialysis dementia has multifactoral causation and is probably not caused by elevated brain content of Al+3 alone.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434672     DOI: 10.7326/0003-4819-90-5-741

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  26 in total

1.  Aluminum transport and dialysance during haemodialysis.

Authors:  S Hosokawa; H Nishitani; T Nishio; T Imai; Y Tomita; T Tomoyoshi; K Sawanishi; O Yoshida
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

Review 2.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

3.  Review of epidemiologic studies of aluminium and neurological disorders.

Authors:  G F Craun
Journal:  Environ Geochem Health       Date:  1990-03       Impact factor: 4.609

4.  Twenty-six week toxicity study with KASAL® (basic sodium aluminum phosphate) in beagle dogs.

Authors:  J C Pettersen; D S Hackett; G M Zwicker; G L Sprague
Journal:  Environ Geochem Health       Date:  1990-03       Impact factor: 4.609

5.  Aluminum and the pathogenesis of dialysis dementia.

Authors:  A I Arieff
Journal:  Environ Geochem Health       Date:  1990-03       Impact factor: 4.609

6.  Differentiated neuroblastoma cells are more susceptible to aluminium toxicity than developing cells.

Authors:  M Roll; E Banin; H Meiri
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

7.  Psychopathology of chronic haemodialysis: is it a behavioural cognitive continuum?

Authors:  R D Alarcon; C S Jenkins; P E Parker; A M Freeman
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

Review 8.  [Aluminum toxicity].

Authors:  H V Henning
Journal:  Klin Wochenschr       Date:  1989-12-15

9.  Inhibition of corticosterone binding in vitro, in rabbit hippocampus, by chromatin bound aluminum.

Authors:  C Sanderson; D R McLachlan; U De Boni
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

10.  Effect of aluminum on normal and uremic rats: tissue distribution, vitamin D metabolites, and quantitative bone histology.

Authors:  Y L Chan; A C Alfrey; S Posen; D Lissner; E Hills; C R Dunstan; R A Evans
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.